CN104945456A - 2-(1',2',3'-triazolyl-4'-oxymethylenepyridyl)-1,3,4,6-O-acetyl-D-glucose and its preparation method and use - Google Patents

2-(1',2',3'-triazolyl-4'-oxymethylenepyridyl)-1,3,4,6-O-acetyl-D-glucose and its preparation method and use Download PDF

Info

Publication number
CN104945456A
CN104945456A CN201510301495.6A CN201510301495A CN104945456A CN 104945456 A CN104945456 A CN 104945456A CN 201510301495 A CN201510301495 A CN 201510301495A CN 104945456 A CN104945456 A CN 104945456A
Authority
CN
China
Prior art keywords
glucose
acetyl
propargyl ether
reaction
pyridyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201510301495.6A
Other languages
Chinese (zh)
Other versions
CN104945456B (en
Inventor
付伯桥
覃彩芹
吕珑
李伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hubei Engineering University
Original Assignee
Hubei Engineering University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hubei Engineering University filed Critical Hubei Engineering University
Priority to CN201510301495.6A priority Critical patent/CN104945456B/en
Publication of CN104945456A publication Critical patent/CN104945456A/en
Application granted granted Critical
Publication of CN104945456B publication Critical patent/CN104945456B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses 2-(1',2',3'-triazolyl-4'-oxymethylenepyridyl)-1,3,4,6-O-acetyl-D-glucose with anti-rectal cancer activity. The 2-(1',2',3'-triazolyl-4'-oxymethylenepyridyl)-1,3,4,6-O-acetyl-D-glucose has a core structure of 1,3,4,6-O-acetyl-D-glucose subjected to 1,2,4-triazole derivative 2-site substitution. The above compound has good rectal cancer cell inhibition activity and can be used as a drug for resisting rectal cancer. A compound synthesis method comprises that 2-amino-D-glucose hydrochloride and an azidation reagent as raw materials undergo a reaction under alkaline conditions to produce a 2-azido-1,3,4,6-O-acetyl-D-glucose intermediate, 3-propargyl bromide and aromatic methanol undergo a reaction under the action of sodium hydride to produce aromatic propargyl ether, and the 2-azido-1,3,4,6-O-acetyl-D-glucose intermediate and the aromatic propargyl ether undergo a click reaction in a solvent in the presence of monovalent copper as a catalyst to produce 2-(1', 2', 3'-triazolyl-4'-oxymethylenepyridyl)-1,3,4,6-O-acetyl-D-glucose.

Description

2-(1 ', 2 ', 3 '-triazole-4 '-Oxymethylene pyridine)-1,3,4,6-O-acetyl-D-glucose and its preparation method and application
Technical field
The present invention relates to the compound 2-(1 ' with anti-tumor activity, 2 ', 3 '-triazole-4 '-Oxymethylene pyridine)-1,3,4,6-O-acetyl-D-glucose and its preparation method and application.
The invention provides the compound 2-(1 ' with good anti-rectum cancer activity, 2 ', 3 '-triazole-4 '-Oxymethylene pyridine)-1,3,4,6-O-acetyl-D-glucose 8.
Background technology
Cancer between the rectum cancer refers to from dentate line to proctosigmoid intersection is one of modal malignant tumour of digestive tube.Rectum cancer position is low, is easily diagnosed by rectal touch and sigmoidoscope.At present, the treatment of the rectum cancer needs based on surgical operation, is aided with the complex therapy of chemotherapy, radiotherapy.For operative treatment, because pelvic cavity is goed deep in its position, anatomy relationship is complicated, and operation is not easily thorough, and Postoperative recurrent rate is high.Middle and lower rectal carcinoma and anal sphincter close, being difficult to the difficult problem that anus preserving and function thereof are operations during operation, is also operation method is argued maximum a kind of diseases.Normal cell also can kill by chemotherapy, radiotherapy while killing cancer cells, can also cause the side effect such as gastrointestinal dysfunction, bone marrow depression, greatly reduces the life quality of patient.Therefore, find a kind of medicine replacing or partly replace operation, chemotherapy, radiotheraping method, tool is of great significance.
The compound 2-(1 ' that the present invention relates to, 2 ', 3 '-triazole-4 '-Oxymethylene pyridine)-1,3,4,6-O-acetyl-D-glucose have good anti-tumor activity through detecting, and are the new compounds having no bibliographical information.The present invention's raw material used is 2-glucosamine is can from the product of degradation of chitosan.Chitosan in animal body be degraded into 2-glucosamine.Chitosan also has bibliographical information to have antineoplastic biological activity.After monomer whose 2-bit amino derivatize, the bioactivity research of new compound, the research for its corresponding polymkeric substance provides corresponding theories integration.Therefore the derivative of 1,2,3-triazoles class is introduced in the 2-position of 2-glucosamine.In addition Novel stack nitrogenize 4 is adopted in the present invention.Compound 4 preparation have raw material cheap, can prepare in a large number.Can deposit and have the good advantage such as water-soluble at normal temperatures.Overcome conventional nitrine reagent as TfN 3have good water-soluble simultaneously.
Summary of the invention:
Technical problem to be solved by this invention is to provide a kind of compound 2-(1 ' with good anti-rectum cancer activity, 2 ', 3 '-triazole-4 '-Oxymethylene pyridine)-1,3,4,6-O-acetyl-D-glucose and preparation method thereof.
Technical scheme provided by the invention is:
2-(1 ', 2 ', 3 '-triazole-4 '-Oxymethylene pyridine)-1,3,4,6-O-acetyl-D-glucose 8, its structural formula is as follows:
Present invention also offers above-claimed cpd 8synthetic method, comprise the following steps:
Step one: generate 2-nitrine-1,3,4,6-O-acetyl-D-glucose intermediate for raw material reacts in the basic conditions with 2-amino-D-Glucose hydrochloride and azide reagent;
Step 2: 3-propargyl bromide and 2-piconol, 3-piconol or 4-piconol (or 3-propargyl alcohol, bromine methylene pyridine/chlorine methylene pyridine) react and generate 2-pyridyl propargyl ether, 3-pyridyl propargyl ether or 4-pyridyl propargyl ether under the effect of mineral alkali.
Step 3: 2-nitrine-1; 3; 4; click-reaction is there is in a solvent and generates 2-(1 ' in 6-O-acetyl-D-glucose intermediate and 4-pyridyl propargyl ether, 3-pyridyl propargyl ether or 2-pyridyl propargyl ether under monovalence copper (sodium ascorbate and cupric salt as: the in-situ preparation such as copper sulfate, venus crystals, trifluoromethayl sulfonic acid copper) catalysis; 2 ', 3 '-triazole-4 '-Oxymethylene pyridine)-1,3; 4,6-O-acetyl-D-glucose 8.Wherein 2-(1 '; 2 ', 3 '-triazole-4 '-Oxymethylene-DB3)-1,3; 4; 6-O-acetyl-D-glucose 8a, 2-(1 ', 2 '; 3 '-triazole-4 '-Oxymethylene-β-pyridine)-1; 3,4,6-O-acetyl-D-glucose 8b and 2-(1 '; 2 '; 3 '-triazole-4 '-Oxymethylene-α-pyridine)-1,3,4; 6-O-acetyl-D-glucose 8c is by 4-pyridine propargyl ether, 3-pyridine propargyl ether and 2-pyridine propargyl ether and 2-nitrine-1 respectively; 3,4,6-O-acetyl-D-glucose intermediate reaction obtains.
Azide reagent in above-mentioned steps one is one of the reagent of trifyl nitrine, imidazoles-1-alkylsulfonyl azide salt hydrochlorate; Solvent is acetonitrile, methyl alcohol, N, one of N '-dimethyl methane amide and dimethyl sulfoxide (DMSO).
Reaction in above-mentioned steps two is at solvents tetrahydrofurane or N, carries out and complete under room temperature or heated reflux condition in N '-dimethyl methane amide; Mineral alkali is sodium hydride, salt of wormwood, sodium carbonate or cesium carbonate.
After the reaction of above-mentioned steps one completes, through washing, dry, filter, recrystallization and column chromatography obtain 2-nitrine-1,3,4,6-O-acetyl-D-glucose intermediate.
The temperature of reaction of above-mentioned steps two is room temperature, and the reaction times is 2-10 hours.
After above-mentioned steps two has been reacted, obtain intermediate 4-pyridyl propargyl ether, 3-pyridyl propargyl ether or 2-pyridyl propargyl ether through cancellation, extraction, washing, drying, filtration and evaporating column chromatography.
The click-reaction of above-mentioned steps three is at 60-100 DEG C of backflow 3 – after 4 hours, or 60-100 DEG C of reactions 0.5-1 hour under microwave condition; React in rear cooling impouring water, through extraction, drying, concentrated and obtain product 2-(1 ', 2 ' after column chromatography; 3 '-triazole-4 '-Oxymethylene-DB3)-1,3,4; 6-O-acetyl-D-glucose 8a, or 2-(1 ', 2 '; 3 '-triazole-4 '-Oxymethylene-β-pyridine)-1,3,4; 6-O-acetyl-D-glucose 8b or 2-(1 ', 2 ', 3 '-triazole-4 '-Oxymethylene-α-pyridine)-1; 3,4,6-O-acetyl-D-glucose 8c.
The present invention adopts cheap 2-amino-D-Glucose hydrochloride to be that raw material prepares 2-(1 ' through three-step reaction, 2 ', 3 '-triazole-4 '-Oxymethylene pyridine)-1,3,4,6-O-acetyl-D-glucose.
Compound 8 of the present invention has the activity of the anti-rectum cancer, can as the application of active medicine in the medicine of the anti-rectum cancer of preparation.
The syntheti c route of the compounds of this invention 8:
Embodiment
Following instance further illustrates the present invention, and does not mean that limitation of the present invention:
Embodiment one: 2-nitrine-1,3,4,6-O-acetyl-D-glucose intermediate synthesizes, and methyl alcohol makees solvent, and nitrine reagent is trifyl nitrine.
Weigh Compound 1(4.313 g, 20 mmol) are dissolved in and are added with triethylamine (7.5 mL, 54 mmol) and CuSO 4.5H 2o(50 mg, 0.2 mmol) water (84 mL) solution in, be filled with nitrogen protection, then Keep agitation 30 minutes under ice-water bath condition.Compound is added when constantly stirring 2(5.030 g, 24 mmol), sustained reaction removes ice-water bath after half an hour, makes system react 24 hours at normal temperatures.
TLC detection reaction.Pressure reducing and steaming solvent.Resistates 50 mL methylbenzene azeotropics dewater.After adding pyridine (100 mL, 20 mmol) in above-mentioned resistates, slowly drip Ac 2o (15 mL, 160 mmol), stirring is spent the night.Underpressure distillation goes out solvent, adds 50 mL water in resistates.Be extracted with ethyl acetate.Organic phase adds 5% (weight percent) HCl 20 mL and washs.Merge the organic layer after extraction, then organic layer uses anhydrous magnesium sulfate drying, collects filtrate after suction filtration, and underpressure distillation is except desolventizing.Resistates is purified through silica gel (200-300 order) column chromatography, and eluent (PE: EA=4: 1), is monitored by TLC, and the product obtained is removed eluent under the condition of underpressure distillation.Finally obtain product 3(5.23 g, yield is 71%).
The synthesis of embodiment two: 4-pyridyl propargyl ether 7a, tetrahydrofuran (THF) makees solvent.
Take 4-piconol (303 mg, 2.774 mmol), be dissolved in dry tetrahydrofuran (THF) (2 mL).Then use nitrogen protection, frozen water is bathed outward, stirs 30 minutes.Take NaH(133 mg, 3.329 mmol), join in solution, react 30 minutes.Then 3-propargyl bromide (413 mg, 3.472mmol) is added.Continuation reaction adds 1mL water and carry out cancellation under condition of ice bath after 3 hours.Extract with 100mL methylene dichloride, extract three times.Use TLC to detect, developping agent (PE: EA=4: 1) confirms to react completely.Silicagel column is used to purify, leacheate (PE: EA=2: 1).Product carries out underpressure distillation except desolventizing, finally obtains product 7a (151 mg, yield is 37%).
The synthesis of embodiment three 3-pyridine propargyl ether 7b, N, N '-dimethyl methane amide makees solvent.
Take 3-piconol (300 mg, 2.74 mmol), be dissolved in dry N, in N '-dimethyl methane amide (5 mL).Then use nitrogen protection, frozen water is bathed outward, stirs 30 minutes.Take NaH(132 mg, 3.288 mmol), join in solution, react 30 minutes.Then 3-propargyl bromide (62.3 mg, 3.288mmol) is added.Continuation reaction adds 1mL water and carry out cancellation under condition of ice bath after 3 hours.Extract with 100mL methylene dichloride, extract three times.Use TLC to detect, developping agent (PE: EA=4: 1) confirms to react completely.Silicagel column is used to purify, leacheate (PE: EA=2: 1).Product carries out underpressure distillation except desolventizing, finally obtains product 7b (231 mg, yield is 64%).
The synthesis of embodiment four: 2-pyridine propargyl ether 7c, acetonitrile solvent.
Take 2-piconol (300 mg, 2.74 mmol), be dissolved in dry acetonitrile (5 mL).Then use nitrogen protection, frozen water is bathed outward, stirs 30 minutes.Take salt of wormwood (460 mg, 6.9 mmol), join in solution, react 30 minutes.Then 3-propargyl bromide (413 mg, 3.472mmol) is added.Continuation reaction adds 1mL water and carry out cancellation under condition of ice bath after 3 hours.Extract with 100mL methylene dichloride, extract three times.Use TLC to detect, developping agent (PE: EA=4: 1) confirms to react completely.Silicagel column is used to purify, leacheate (PE: EA=2: 1).Product carries out underpressure distillation except desolventizing, finally obtains product 2-pyridine propargyl ether 7c (320 mg, yield is 79%).
Embodiment five: the trimethyl carbinol and water make solvent, synthesis 2-(1 ', 2 ', 3 '-triazole-4 '-Oxymethylene-DB3)-1,3,4,6-O-acetyl-D-glucose.
Weigh Compound 3 (139 mg, 0.3706 mmol), add in pear shape bottle, be dissolved in the mixed solvent of the 2 mL trimethyl carbinols and water (volume ratio 1:1), add compound 4-pyridyl propargyl ether (60 mg, 0.4077 mmol), CuSO 4.5H 2o (4.6 mg, 0.02 mmol) and sodium ascorbate (7.4 mg, 0.03706 mmol).React 4 hours at 100 DEG C.Pressure reducing and steaming solvent.Residue is dissolved in 20 mL water, extracts three times by ethyl acetate (20 mL), then by the solution anhydrous Na SO after extraction 4drying, filters.Filtrate decompression evaporate to dryness.Silica column purification, leacheate is PE: EA=1: 2.By the part mixing solutions containing product, by Rotary Evaporators underpressure distillation, isolate solvent, after drying, obtain product 8a(107mg, yield is 55.5%).Product is the mixture of β and α configuration.Wherein β: α=100: 37.
IR: υ = 1742, 1205, 1028 cm -1;
1h NMR (400 MHz, CDCl 3): (α/β=37:100) α configuration: δ=8.59 (d, j=8.0 Hz, 2H) 7.68 (s, 1 H, H-C triazol), 7.26 (d, j=8.0 Hz, 2H), 6.39 (d, j=3.6 Hz, 1 H, H-C), 5.99-5.94 (m; 1 H, H-C), 5.31-5.16 (m, 1 H; H-C), 4.79 (s, 2 H, H-C); 4.71-4.66 (m, 1 H, H-C, 4.42-4.38 (m; 1 H, H-C), 4.19-4.10 (m, 2H; H-C), 2.16-1.88 (m, 12 H, 4AcO) ppm;
Beta comfiguration: δ=8.59 (d, j=8.0 Hz, 2H), 7.63 (s, 1 H, H-C), 7.26 (d, j=8.0 Hz, 2H), 6.20 (d, j=8.4 Hz, 1 H, H-C (1)), 5.84-5.79 (m; 1 H, H-C), 5.21 (m, 1 H; H-C), 4.78 (s, 2 H, H-C); 4.71-4.66 (m, 1 H, H-C), 4.42 – 4.38 (m; 1 H, H-C), 4.19-4.10 (m, 2H; H-C), 2.16-1.88 (m, 12 H, 4AcO) ppm;
13C NMR (100 MHz, CDCl 3): α/β, δ = 170.56， 170.54， 169.58， 169.10， 168.10， 149.86， 146.82， 145.10， 144.89， 122.7，121.75， 91.53，89.98， 72.94， 72.03， 70.43， 69.83，68.71， 67.99， 63.87， 62.68， 61.21， 60.38， 20.68， 20.66， 20.52， 20.50， 20.31， 20.20 ppm.
HRMS:M+ Na +: C 23h 28n 4naO 10,theoretical value: 543.1703, measured value: 543.1714.
Embodiment six: DMF makees solvent, synthesis 2-(1 ', 2 ', 3 '-triazole-4 '-Oxymethylene-β-pyridine)-1,3,4,6-O-acetyl-D-glucose 8b.
Weigh Compound 3 (300 mg, 0.8036 mmol), adds in pear shape bottle, is dissolved in 1 mL DMF, adds compound 3-pyridyl propargyl ether (129 mg, 0.9643 mmol), CuSO 4.5H 2o (10 mg, 0.04018 mmol) and sodium ascorbate (16 mg, 0.08036 mmol).Microwave reaction 0.5 hour at 100 DEG C.Pressure reducing and steaming solvent.Residue is dissolved in 10 mL water, extracts three times by ethyl acetate (20 mL), then by the solution anhydrous Na SO after extraction 4drying, filters.Filtrate decompression evaporate to dryness.Silica column purification, leacheate is PE: EA=1: 4.By the part mixing solutions containing product, by Rotary Evaporators underpressure distillation, isolate solvent, after drying, obtain product 8b(261.7mg, yield is 62.4%).Product is the mixture of β and α configuration.Wherein β: α=100: 27.
IR: υ = 1743, 1361, 1211, 1027, 786, 708 cm -1;
1h NMR (400 MHz, CDCl 3): (α/β=100: 27) α configuration: δ=8.68 (s, 1 H, H-C), 8.60 (s, 1 H, H-C), 7.94 (d, j=8 Hz, 1 H, H-C), 7.53-7.51 (t, j=8 Hz, 1 H, H-C), 7.71 (s, 1 H, H-C), 6.39 (d, j=4 Hz, 1 H, H-C), 5.98-5.93 (t, j=20 Hz, 1 H, H-C), 5.31-5.16 (m, 1 H, H-C), 4.78 (d, j=8 Hz, 2 H, H-C), 4.73-4.63 (m, 1 H; H-C), 4.41-4.28 (m, 1 H, H-C), 4.18-4.06 (m; 2 H, H-C), 2.11-1.70 (m, 12 H, 4AcO) ppm;
Beta comfiguration: δ=8.68 (s, 1 H, H-C), 8.60 (s, 1 H, H-C), 7.94 (d, j=8 Hz, 1 H, H-C), 7.53-7.51 (t, j=8 Hz, 1H, H-C), 7.67 (d, j=8 Hz, 1 H, H-C), 6.21 (d, j=8 Hz, 1 H, H-C), 5.78-5.73 (t, j=20 Hz, 1 H, H-C), 5.31-5.16 (m, 1 H, H-C), 4.78 (d, j=8 Hz, 2 H, H-C), 4.73-4.63 (m, 1 H; H-C), 4.41-4.28 (m, 1 H, H-C), 4.18-4.06 (m; 2 H, H-C), 2.11-1.70 (m, 12 H, 4AcO) ppm;
13c NMR (100 MHz, containing α and beta comfiguration, CDCl 3): δ=170.50,169.30,168.07,167.67,149.19,144.97,135.54,133.05,132.20,130.87,128.76,123.40,122.78,121.75,91.50,89.96,72.86,71.99,69.71,68.71,68.00,65.50,63.60,62.65,61.20,20.64,20.48,20.46,20.26,20.17,19.09 ppm.
Embodiment seven: DMF makees solvent, synthesis 2-(1 ', 2 ', 3 '-triazole-4 '-Oxymethylene-α-pyridine)-1,3,4,6-O-acetyl-D-glucose 8c.Weigh Compound 3 (200 mg, 0.5357 mmol), adds in pear shape bottle, is dissolved in 1 mL DMF, adds compound 2-pyridyl propargyl ether (78.5 mg, 0.5893 mmol), CuSO 4 .5H 2o (7 mg, 0.02679 mmol) and sodium ascorbate (11 mg, 0.05357 mmol).Microwave reaction 0.5 hour at 100 DEG C.Pressure reducing and steaming solvent.Residue is dissolved in 10 mL water, extracts three times by ethyl acetate (20 mL), then by the solution anhydrous Na SO after extraction 4drying, filters.Filtrate decompression evaporate to dryness.Silica column purification, leacheate is PE: EA=1: 4.By the part mixing solutions containing product, by Rotary Evaporators underpressure distillation, isolate solvent, after drying, obtain product 8b(118mg, yield is 43.4%).Product is the mixture of β and α configuration.Wherein β: α=100: 27.
1h NMR (400 MHz, CDCl3): (α/β=100: 27) α configuration: δ=8.62-8.59 (t, j=12 Hz, 1 H, H-C), 7.88-7.83 (t, j=20 Hz, 1H, H-C), 7.57-7.53 (m, 1H, H-C), 7.36-7.33 (t, j=12 Hz, 1H, H-C), 7.71 (d, j=8 Hz, 1 H, H-C), 6.39 (d, j=4 Hz, 1 H, H-C), 5.99-5.94 (t, j=20 Hz, 1 H, H-C), 5.31-5.20 (m; 1 H, H-C), 4.78 (s, 2 H; H-C), 4.71-4.66 (m, 1 H, H-C); 4.42-4.29 (m, 1 H, H-C); 4.18-4.05 (m, 2 H, H-C); 2.13-1.70 (m, 12 H, 4AcO) ppm;
Beta comfiguration: δ=8.62-8.59 (t, j=12 Hz, 1 H, H-C), 7.88-7.83 (t, j=20 Hz, 1 H, H-C), 7.57-7.53 (m, 1 H, H-C), 7.36-7.33 (t, j=12 Hz, 1 H, H-C), 7.74 (d, j=16 Hz, 1 H, H-C), 6.21 (d, j=8 Hz, 1 H, H-C), 5.83-5.77 (t, j=24 Hz, 1 H, H-C), 5.31-5.20 (m; 1 H, H-C), 4.78 (s, 2 H; H-C), 4.71-4.66 (m, 1 H, H-C); 4.42-4.29 (m, 1 H, H-C); 4.18-4.05 (m, 2 H, H-C); 2.13-1.70 (m, 12 H, 4AcO) ppm;
13c NMR (100 MHz, containing α/β configuration, CDCl3): δ=170.52,169.59,169.08,168.07,157.59,149.16,145.05,136.70,130.88,128.78,122.70,121.67,91.55,89.98,73.00,72.03,69.75,68.70,68.00,65.51,63.99,61.91,61.10,20.63,20.38,19.65 ppm.
Can find out that the compound shown in compound 8 has good rectum cancer biological activity from experiment below.
Example eight
Experimental technique
(1) cell cultures
Colorectal cancer cell lines HCT116 is stored in liquid nitrogen for a long time by this laboratory, is incubated in the substratum RPMI substratum 1640 (GIBCO) containing 10% foetal calf serum, is placed in 37oC, saturated humidity and 5% CO before using 2incubator cellar culture, within every 2 ~ 4 days, go down to posterity, the cell in vegetative period of taking the logarithm is tested.
(2) MTS cytotoxicity experiment
The cell colorectal cancer cell HCT116 taken the logarithm vegetative period prepares cell suspension, is seeded in 96 porocyte culture plates, and overnight incubation in containing the substratum of 10%FBS, adds the compound of different concns for second day, at 5% CO 2incubator is cultivated; 72h stops cultivating, and add MTS (Promega), 37 oC hatch 1-4 hour, and microplate reader (Thermo Scientific Varioskan Flash) reads light absorption value in 490nm.Calculate cytotoxicity IC 50.Distinguish in triplicate.Average.
The IC of compound 8a 50the IC of=2.58 uM, 8b 50the IC of=3.67 uM, 8c 50=5.58 uM .
Experiment shows: the compound 8 in the present invention has the activity of the good anti-rectum cancer, also can be used as the inhibitor of tumour.
Example nine
Nude mice by subcutaneous inoculates into knurl animal model and detection
Get 6-8 BALB/c strain male nude mouse in age in week 40, prepare the CRC cell suspension that number is 1 × 107/ml, subcutaneous injection nude mice, 100ul/ only.1-2 observes into knurl situation in week, after tumour can be touched, be equally divided into drug treating group and control group according to tumorous size.Drug treating group arranges basic, normal, high dosage group according to previous experiments result, and subcutaneous injection in every 3 days is about 0.1-0.3ml/10g compound, control group subcutaneous injection normal saline, administration in continuous 2 weeks.The every 3 days maximum diameter (L by a vernier caliper measurement tumour, and most path (w mm), mm), calculate gross tumor volume Volume (mm3)=L × W2 × 0.4, draw tumor volume growth curve, become knurl experiment to terminate (about 4-6 week) and put to death mouse (the excessive anesthesia of 3% vetanarcol is lethal) afterwards, collect tumor specimen, be kept in liquid nitrogen and 10% formalin fixing respectively, for extracting, albumen and RNA and immunohistochemical methods are used.Collect the result of the weight contrast of tumour: use compound 8a, after 8b, 8c, the weight of tumour only has 30%-40%, 40%-50%, 50%-60% of blank respectively.

Claims (9)

1.2-(1 ', 2 ', 3 '-triazole-4 '-Oxymethylene pyridine)-1,3,4,6-O-acetyl-D-glucose, its structural formula is as follows:
In formula, R is , or .
2. 2-(1 ' described in claim 1,2 ', 3 '-triazole-4 '-Oxymethylene pyridine) synthetic method of-1,3,4,6-O-acetyl-D-glucose, it is characterized in that comprising the following steps:
Step one: generate 2-nitrine-1,3,4,6-O-acetyl-D-glucose intermediate for raw material reacts in the basic conditions with 2-amino-D-Glucose hydrochloride and azide reagent;
Step 2: 3-propargyl bromide and 2-piconol, 3-piconol or 4-piconol react and generate 2-pyridyl propargyl ether, 3-pyridyl propargyl ether or 4-pyridyl propargyl ether under the effect of mineral alkali;
Step 3: 2-nitrine-1; 3; 4; click-reaction is there is in a solvent and generates 2-(1 ' in 6-O-acetyl-D-glucose intermediate and 4-pyridyl propargyl ether, 3-pyridyl propargyl ether or 2-pyridyl propargyl ether under the catalysis of monovalence copper; 2 ', 3 '-triazole--Oxymethylene pyridine)-1,3; 4,6-O-acetyl-D-glucose.
3. synthetic method according to claim 2, is characterized in that: the azide reagent in step one is one of the reagent of trifyl nitrine, imidazoles-1-alkylsulfonyl azide salt hydrochlorate; Solvent is acetonitrile, methyl alcohol, N, one of N '-dimethyl methane amide and dimethyl sulfoxide (DMSO).
4. synthetic method according to claim 2, is characterized in that: the reaction in step 2 is at solvents tetrahydrofurane or N, carries out and complete under room temperature or heated reflux condition in N '-dimethyl methane amide; Mineral alkali is sodium hydride, salt of wormwood, sodium carbonate or cesium carbonate.
5. synthetic method according to claim 2, is characterized in that: after the reaction of step one completes, through washing, dry, filter, recrystallization and column chromatography obtain 2-nitrine-1,3,4,6-O-acetyl-D-glucose intermediate.
6. synthetic method according to claim 3, is characterized in that: the temperature of reaction of step 2 is room temperature, and the reaction times is 2-10 hours.
7. synthetic method according to claim 2, it is characterized in that: after step 2 has been reacted, obtain intermediate 2-pyridyl propargyl ether, 3-pyridyl propargyl ether or 4-pyridyl propargyl ether through cancellation, extraction, washing, drying, filtration and evaporating column chromatography.
8. synthetic method according to claim 2, is characterized in that: the click-reaction of step 3 is at 60-100 DEG C of backflow 3 – after 4 hours, or 60-100 DEG C of reactions 0.5-1 hour under microwave condition; React in rear cooling impouring water, through extraction, drying, concentrated and obtain product 2-(1 ', 2 ', 3 '-triazole-4 after column chromatography '-Oxymethylene-pyridine)-1,3,4,6-O-acetyl-D-glucose.
9. the application of compound described in claim 1 in the medicine of the anti-rectum cancer of preparation.
CN201510301495.6A 2015-06-04 2015-06-04 2‑（The Oxymethylene pyridine of 1 ', 2 ', 3 ' triazole 4 '）1,3,4,6 O acetyl group D glucose and its preparation method and application Active CN104945456B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510301495.6A CN104945456B (en) 2015-06-04 2015-06-04 2‑（The Oxymethylene pyridine of 1 ', 2 ', 3 ' triazole 4 '）1,3,4,6 O acetyl group D glucose and its preparation method and application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510301495.6A CN104945456B (en) 2015-06-04 2015-06-04 2‑（The Oxymethylene pyridine of 1 ', 2 ', 3 ' triazole 4 '）1,3,4,6 O acetyl group D glucose and its preparation method and application

Publications (2)

Publication Number Publication Date
CN104945456A true CN104945456A (en) 2015-09-30
CN104945456B CN104945456B (en) 2018-01-05

Family

ID=54160571

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510301495.6A Active CN104945456B (en) 2015-06-04 2015-06-04 2‑（The Oxymethylene pyridine of 1 ', 2 ', 3 ' triazole 4 '）1,3,4,6 O acetyl group D glucose and its preparation method and application

Country Status (1)

Country Link
CN (1) CN104945456B (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107652338A (en) * 2017-10-31 2018-02-02 天津大学 The polycyclic aromatic hydrocarbon derivative of sugar coupling 1,2,3 triazoles substitution is preparing the purposes of cancer therapy drug
CN109336940A (en) * 2018-11-13 2019-02-15 河南师范大学 Acridone derivatives and its preparation method and application of the one kind containing galactolipin
CN109369745A (en) * 2018-11-13 2019-02-22 河南师范大学 Acridone derivatives and its preparation method and application of the one kind containing glucose
CN112899081A (en) * 2021-01-19 2021-06-04 云南中烟工业有限责任公司 Preparation method and application of DGP (DGP-protein) substance
CN113149897A (en) * 2021-03-24 2021-07-23 福建省中科生物股份有限公司 2, 6-substituted-4-oxyterpene phenol pyridine compound and preparation method and application thereof
CN113429445A (en) * 2021-05-13 2021-09-24 绍兴文理学院元培学院 Isoxazole derivative containing arabinose triazole structure and preparation method and application thereof
CN113429446A (en) * 2021-05-13 2021-09-24 绍兴文理学院元培学院 Isoxazole derivative containing xylose triazole structure and preparation method and application thereof
CN113444133A (en) * 2021-05-13 2021-09-28 绍兴文理学院元培学院 Isoxazole derivative containing glucose triazole structure and preparation method and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113569A1 (en) * 2004-05-21 2005-12-01 Forskapatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
CN101475615A (en) * 2008-12-05 2009-07-08 华东理工大学 Amino acid glucide compound and its use
WO2012116196A2 (en) * 2011-02-24 2012-08-30 Board Of Regents, The University Of Texas System Substituted lactosyl compounds and use thereof for cellular imaging and therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113569A1 (en) * 2004-05-21 2005-12-01 Forskapatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
CN101475615A (en) * 2008-12-05 2009-07-08 华东理工大学 Amino acid glucide compound and its use
WO2012116196A2 (en) * 2011-02-24 2012-08-30 Board Of Regents, The University Of Texas System Substituted lactosyl compounds and use thereof for cellular imaging and therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
吕珑，等: "1,3,4,6-四-O-乙酰基-β-D-氨基葡萄糖盐酸盐的制备及其还原性研究", 《湖北工程学院学报》 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107652338A (en) * 2017-10-31 2018-02-02 天津大学 The polycyclic aromatic hydrocarbon derivative of sugar coupling 1,2,3 triazoles substitution is preparing the purposes of cancer therapy drug
CN107652338B (en) * 2017-10-31 2021-02-26 天津大学 Application of sugar coupling-1, 2, 3-triazole substituted polycyclic aromatic hydrocarbon derivative in preparation of anti-cancer drugs
CN109336940A (en) * 2018-11-13 2019-02-15 河南师范大学 Acridone derivatives and its preparation method and application of the one kind containing galactolipin
CN109369745A (en) * 2018-11-13 2019-02-22 河南师范大学 Acridone derivatives and its preparation method and application of the one kind containing glucose
CN112899081A (en) * 2021-01-19 2021-06-04 云南中烟工业有限责任公司 Preparation method and application of DGP (DGP-protein) substance
CN113149897A (en) * 2021-03-24 2021-07-23 福建省中科生物股份有限公司 2, 6-substituted-4-oxyterpene phenol pyridine compound and preparation method and application thereof
CN113149897B (en) * 2021-03-24 2023-10-31 福建省中科生物股份有限公司 2, 6-substituted-4-oxyterpene phenolic pyridine compound and preparation method and application thereof
CN113429445A (en) * 2021-05-13 2021-09-24 绍兴文理学院元培学院 Isoxazole derivative containing arabinose triazole structure and preparation method and application thereof
CN113429446A (en) * 2021-05-13 2021-09-24 绍兴文理学院元培学院 Isoxazole derivative containing xylose triazole structure and preparation method and application thereof
CN113444133A (en) * 2021-05-13 2021-09-28 绍兴文理学院元培学院 Isoxazole derivative containing glucose triazole structure and preparation method and application thereof

Also Published As

Publication number Publication date
CN104945456B (en) 2018-01-05

Similar Documents

Publication Publication Date Title
CN104817605B (en) 2‑（The oxygen benzyl of 1 ', 2 ', 3 ' triazole 4 '）1,3,4,6 O acetyl group D glucose and its preparation method and application
CN104945456A (en) 2-(1',2',3'-triazolyl-4'-oxymethylenepyridyl)-1,3,4,6-O-acetyl-D-glucose and its preparation method and use
CN102083429B (en) Ido inhibitors
CA2680778C (en) Fused amino pyridine as hsp90 inhibitors
CN104411701B (en) Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer
CN103804312B (en) Aza cyclic cpds and its production and use
WO2006129623A1 (en) Thienotriazolodiazepine compound and a medicinal use thereof
CN104119330B (en) The synthesis of berberinc derivate and preparing the application in antitumor drug and collaborative Zorubicin antineoplastic pharmaceutical compositions
CN106478605A (en) Pyrimidines, its preparation method and medical usage
CN106661025A (en) Hydroxyethyl sulfonate of cyclin-dependent protein kinase inhibitor, crystalline form thereof and preparation method therefor
EP3383877B1 (en) Heterocycle compounds and uses thereof
CN104945457B (en) 1‑（1 ', 3 ', 4 ', 6 '-four O acetyl group α/β D glucopyanosyls）4 contraposition substituted aryl [1,2,3] triazoles and its preparation method and application
CN105017245B (en) Imidazopyridine compound and preparation method and application thereof
CN106831707A (en) As the benzheterocycle analog derivative and its medical application of c Met kinase inhibitors
CN116715657A (en) Diaryl acetylene compound, preparation method and application thereof
CN108358894B (en) Compound for inhibiting histone acetyltransferase as well as preparation method and application thereof
CN110922415A (en) Synthesis and application of novel anti-tumor active compound
CN106588909B (en) A kind of preparation of quinoline derivatives and its application in anti-inflammatory
CN104230836B (en) Phenyl azole compounds and the application in the medicine of preparation treatment cancer
ZA200402626B (en) New hydroxyalkylindolocarbazole compounds, a process for their preparation and pharmaceutical compositions containing them
CN114890928B (en) Isothiocyanate derivative and preparation method and application thereof
CN105237595A (en) N2-glycosyl-substituted 1,2,3-triazole compound and synthesis method and application thereof
KR20210123314A (en) Fluorine-containing substituted benzothiophene compounds, pharmaceutical compositions and applications thereof
CN112724132B (en) Synthetic method of 3-halogenated-5-trifluoromethyl-pyrazolo [1,5-a ] pyridine
CN112300235B (en) Benzimidazole derivative BI321 and preparation method and application thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant